National Pension Service Boosts Stock Position in Illumina, Inc. (NASDAQ:ILMN)

National Pension Service lifted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 12.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 300,661 shares of the life sciences company's stock after buying an additional 33,152 shares during the period. National Pension Service owned about 0.19% of Illumina worth $39,209,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the stock. Industrial Alliance Investment Management Inc. bought a new stake in shares of Illumina in the 2nd quarter worth $34,000. Versant Capital Management Inc boosted its holdings in Illumina by 292.9% during the second quarter. Versant Capital Management Inc now owns 330 shares of the life sciences company's stock worth $34,000 after purchasing an additional 246 shares during the last quarter. Massmutual Trust Co. FSB ADV grew its position in Illumina by 65.1% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 426 shares of the life sciences company's stock worth $56,000 after purchasing an additional 168 shares in the last quarter. nVerses Capital LLC purchased a new stake in Illumina in the 3rd quarter valued at about $65,000. Finally, Itau Unibanco Holding S.A. bought a new position in shares of Illumina during the 2nd quarter worth approximately $61,000. Institutional investors own 89.42% of the company's stock.

Illumina Price Performance

Shares of ILMN traded up $3.32 during mid-day trading on Thursday, reaching $155.15. 2,162,717 shares of the stock traded hands, compared to its average volume of 2,008,265. The company has a current ratio of 1.11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. Illumina, Inc. has a 1 year low of $89.00 and a 1 year high of $156.66. The company has a market cap of $24.72 billion, a price-to-earnings ratio of -15.58 and a beta of 1.13. The firm has a fifty day moving average price of $137.27 and a 200 day moving average price of $123.12.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.26. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.08 billion. Illumina had a positive return on equity of 6.36% and a negative net margin of 36.10%. The company's quarterly revenue was down 3.5% compared to the same quarter last year. During the same period in the prior year, the company earned $0.33 EPS. As a group, equities research analysts predict that Illumina, Inc. will post 3.62 earnings per share for the current year.

Analyst Ratings Changes

A number of analysts recently commented on ILMN shares. Argus raised Illumina from a "hold" rating to a "buy" rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th. Piper Sandler decreased their target price on Illumina from $200.00 to $195.00 and set an "overweight" rating for the company in a research report on Tuesday, August 13th. UBS Group boosted their price target on shares of Illumina from $133.00 to $145.00 and gave the stock a "neutral" rating in a report on Tuesday. Leerink Partners increased their price target on shares of Illumina from $160.00 to $200.00 and gave the company an "outperform" rating in a research report on Thursday, October 17th. Finally, Daiwa America raised shares of Illumina to a "strong-buy" rating in a research report on Friday, August 16th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, Illumina presently has an average rating of "Moderate Buy" and a consensus price target of $162.18.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.